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A hindbrain inhibitory microcircuit
mediates vagally-coordinated
glucose regulation
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Neurons in the brainstem dorsal vagal complex integrate neural and humoral signals to coordinate
autonomic output to viscera that regulate a variety of physiological functions, but how this circuitry
regulates metabolism is murky. We tested the hypothesis that premotor, GABAergic neurons in the
nucleus tractus solitarius (NTS) form a hindbrain micro-circuit with preganglionic parasympathetic
motorneurons of the dorsal motor nucleus of the vagus (DMV) that is capable of modulating systemic
blood glucose concentration. In vitro, neuronal activation or inhibition using either excitatory or
inhibitory designer receptor exclusively activated by designer drugs (DREADDs) constructs expressed
in GABAergic NTS neurons increased or decreased, respectively, action potential firing of GABAergic
NTS neurons and downstream synaptic inhibition of the DMV. In vivo, DREADD-mediated activation of
GABAergic NTS neurons increased systemic blood glucose concentration, whereas DREADD-mediated
silencing of these neurons was without effect. The DREADD-induced hyperglycemia was abolished by
blocking peripheral muscarinic receptors, consistent with the hypothesis that altered parasympathetic
drive mediated the response. This effect was paralleled by elevated serum glucagon and hepatic
phosphoenolpyruvate carboxykinase 1 (PEPCK1) expression, without affecting insulin levels or muscle
metabolism. Activity in a hindbrain inhibitory microcircuit is sufficient to modulate systemic glucose
concentration, independent of insulin secretion or utilization.
The brain orchestrates peripheral responses to changes in blood glucose concentration1–3. Several recent studies
have identified insulin-independent pathways for regulating glucose metabolism4–9, and the role of the brain as a
glucose regulatory organ10 is gaining acceptance. Multiple ‘preautonomic’ areas of the brain contribute to systemic
glucose homeostasis11–13. Much work describing the glucose regulatory function of the brain focuses on the hypothalamic microcircuitry necessary for feeding and satiety6,14–17, but ample evidence indicates that the brainstem
dorsal vagal complex (DVC) plays an important role in modulating plasma glucose and insulin levels, feeding,
and energy balance18–22. Vagally-mediated parasympathetic output critically regulates visceral functions related to
metabolic homeostasis9,23. The cephalic phase of insulin release requires an intact vagus nerve24 and lesioning the
hepatic vagus nerve potently suppresses effects of central insulin application on hepatic gluconeogenesis in diabetic mice25. Moreover, injection of a glucoprivic glucose analogue into the vagal complex, but not hypothalamic
areas, increases both feeding and hyperglycemia in rats18. Neurons in the DVC clearly influence blood glucose
concentration, yet little is known about the circuitry underlying this effect.
Vagal motor output to the thoracic and most abdominal viscera is generated by the preganglionic, parasympathetic motor neurons of the dorsal motor nucleus of the vagus (DMV), making the DMV the final, central
modulatory point in parasympathetic activity. DMV motor neurons are tonically active, but this activity is modulated on a moment-to-moment basis by synaptic inputs from second order viscerosensory neurons in the nucleus
tractus solitarius (NTS); together with the area postrema, these structures comprise the DVC. Microinjection of
nutrient signaling molecules into the DVC alters overall blood glucose concentration18,26,27 and vagal activity28.
Relatively few vagal motor neurons are considered glucose-sensitive29, and the ability to respond to metabolic
changes is likely communicated via synaptic transmission from other nuclei. Neurons throughout the DVC are
directly responsive to a wide range of nutrient and satiety signals, including leptin30,31, insulin26,32,33, lactate34,
and glucose18,29,35–39. In particular, most inhibitory GABAergic neurons within the NTS receive primary vagal
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afferent input40,41 and are themselves glucose responsive35,36, and GABAergic NTS neurons project prominently
to the DMV42 contributing significantly to vagal motor neuron activity43,44. GABA release in the DMV is also
significantly elevated after the induction of diabetes45, consistent with diabetes-induced plasticity of DMV neuronal function46,47, particularly of GABAA receptor activity48,49. Thus, GABA neurons in the NTS are positioned to
potently modulate vagal motor activity in response to neural and circulating metabolic signals, but their influence
on systemic glucose regulation is unknown.
Taken together, the DVC, particularly its GABAergic circuitry, appears ideally situated to regulate peripheral glucose metabolism. However, this function remains controversial. Electrical stimulation of the vagus nerve
causes the release of both insulin and glucagon from the pancreas50–54. However, the release of these hormones
with opposite effects on systemic glucose levels makes it difficult to predict how vagal activity changes modulate
blood glucose concentration. Manipulating activity of glucose sensing neurons in the NTS results in changes in
gastric motility28 and glucagon secretion36, but neither of these assessments probed whether direct modulation
of inhibitory neurocircuitry in the DVC alters blood glucose concentration. We hypothesized that experimentally increasing the activity of GABAergic neurons in the DVC would inhibit DMV motor neurons and increase
blood glucose concentration, whereas experimentally decreasing the activity of GABAergic neurons in this region
would have the opposite effects.

Results

Traditionally, manipulations of neurotransmission in the DVC were accomplished using electrical, photochemical, or pharmacological stimulation methods19,50,55, but these techniques do not provide the phenotype
selectivity needed to target the GABAergic neuron sub-population in the dorsal hindbrain. We stimulated
GABAergic NTS neurons selectively by utilizing a chemogenetic approach, using a stereotaxically injected
cre-recombinase-inducible adeno-associated viruses expressing the chemogenetic designer receptor exclusively
activated by designer drugs (DREADDs) and the fluorescent marker, mCherry, into the DVC of mice that express
cre-recombinase in GABAergic neurons (i.e., vGAT-Cre mice, Slc32a1tm2(cre)lowl/J; the Jackson Laboratories;
stock 016962; Fig. 1a).

Activation of GABAergic Hindbrain Neurons Using hM3Dq-mCherry.

Widespread mCherry+
expression was present throughout the NTS in the dorsal hindbrain 3–4 weeks after viral transduction, the general
distribution of which matched that observed for GABAergic NTS neurons reported previously41,56,57 (Fig. 1b). We
initially tested whether GABAergic NTS neurons expressing hM3Dq-mCherry (AAV8 DIO hM3Dq) increased
their activity in response to the DREADD ligand, clozapine-N-oxide (CNO; 10 µM). mCherry-expressing NTS
neurons were targeted for patch-clamp recordings in acutely prepared brainstem slices (Fig. 1c). A modest,
but consistent and significant depolarization was observed in mCherry-expressing neurons exposed to CNO
(ΔmV = +2.0 ± 0.2 mV; n = 7; p = 0.00002 paired t-test; Fig. 1d). This depolarization was accompanied by a significant increase in action potential firing (2.9 ± 0.6 Hz in normal artificial cerebrospinal fluid (nACSF) versus
3.5 ± 0.5 Hz in CNO; p = 0.002; n = 8). After a 15 minute washout, action potential firing was similar to that prior
to drug treatment (p = 0.2 vs pre-drug application). Application of CNO had no effect on either membrane potential (p > 0.05) or action potential frequency (p > 0.05) in any unlabeled, non-transfected NTS neuron (n = 4). A
randomly-selected subset of recorded mCherry+ neurons expressed GAD67 mRNA, determined by single-cell
RT-PCR35, confirming their GABAergic phenotype (n = 6; data not shown).

Activation of Hindbrain GABAergic Circuits Increases Blood Glucose Concentration. We
employed a counter-balanced experimental design, where each animal served as its own control, wherein 50%
of the animals received one treatment (i.e. vehicle versus CNO) while the other half received the other treatment
on any day of testing, to investigate how activation of GABAergic neurons in the dorsal hindbrain affects blood
glucose concentration. After a two hour fast, baseline blood glucose levels were not different between groups
before receiving saline (169.5 ± 7.6 mg/dL) or CNO injection (162.9 ± 6.6 mg/dL; n = 7; p = 0.5; Fig. 1e). After
systemic CNO (1 mg/kg) intraperitoneal administration, blood glucose concentration rose steadily compared to
an injection of the vehicle (0.9% NaCl + 0.5% DMSO). This rise was apparent within 15 min and became significant at 60–90 minutes (Repeated Measures ANOVA with Tukey’s post-hoc test; interaction p = 0.0002; Fig. 1e).
These data provide direct evidence that increased activity of GABAergic, DVC neurons increases peripheral blood
glucose concentration.
A recent study suggested that CNO may have off-target effects due to potential actions of its metabolites58.
Additional control experiments were performed to test the effect of CNO in animals with no detectable mCherry
expression in the DVC (e.g. injections that missed the DVC), or animals that did not receive hM3Dq-mCherry
virus. Counterbalanced intraperitoneal injections of saline or CNO had no effect on blood glucose concentration
in any of these controls (p = 0.7; n = 7). A significant reduction in blood glucose was observed over time as a result
of fasting conditions in all mice (Repeated Measures ANOVA; time p < 0.0001; Supplemental Fig. S1). However,
there was no difference in the effect on blood glucose concentration of vehicle versus CNO administration in
these mice (Repeated Measures ANOVA; interaction p = 0.3; CNO versus saline p = 0.2; Supplemental Fig. S1).
Therefore, the ability of CNO to increase systemic blood glucose required the activation of hM3Dq-mCherry
expressing GABAergic neurons in the DVC.
Activation of Hindbrain GABAergic Circuits Inhibits Vagal Motor Activity.

Inhibitory neurons
in the NTS send significant, functional projections to preganglionic DMV motor neurons42,44,59, whose axons
course via the vagus nerve to postganglionic neurons located in organs important for glucose metabolism60–62.
Assuming the glucose-altering effects of GABAergic NTS neuron activity was mediated by vagal projections, we
hypothesized that the chemogenetic activation of inhibitory neurons in the DVC would dampen excitability of
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Figure 1. Cre-dependent expression and response to activation of designer receptor exclusively activated by
designer drugs (DREADDs) in dorsal hindbrain GABAergic neurons. (a) Expression of excitatory DREADDs
was induced though a stereotaxic microinjection of pAAV8-hSyn-DIO-hM3Dq into the dorsal vagal complex
(DVC) of a vGAT-Cre mouse. (b) Light microscopic images of endogenous mCherry expression in the DVC.
Left: low magnification image of the DVC. Right: higher magnification centered on the nucleus of the solitary
tract (NTS) three weeks after AAV inoculation. The dorsal motor nucleus of the vagus (X) is encircled.
Expression was prominent in the NTS, but also could include a few GABAergic interneurons located in
the DMV, which have been described previously56. (c) Illustration of the recording configuration, with the
recording pipette in the NTS. Image under combined fluorescent and IR/DIC illumination during a recording
from an mCherry expressing NTS neuron is to the right of the diagram. Recording pipette is visible attached
to an mCherry expressing neuron. Lower. Images of an NTS neuron that was filled with biocytin during a
recording and was visualized post hoc with AMCA (left); the same section using a filter to visualize mCherry
(middle); and merged images (right) demonstrating that the recorded neuron expressed mCherry. (d) Top:
Action potentials in an mCherry expressing NTS neuron recorded under control conditions (nACSF) and in
the presence of clozapine-N-oxide (CNO; 10 µM) Bottom: Mean (±SEM) membrane potential (mV) and action
potential firing rate (Hz) were both significantly affected by CNO application (n = 8; p < 0.05). (e) Blood glucose
concentration after intraperitoneal (i.p.) administration of CNO (1 mg/kg) or vehicle (0.9% saline + 0.5%
DMSO). Asterisks indicate significant effect of CNO (p < 0.05). Inset: Graph of mean fasted blood glucose
concentration in vivo before CNO or vehicle administration. No differences were detected prior to treatment.
DMV motor neurons. Using whole-cell voltage-clamp recordings from brainstem slices, we assessed whether
hM3Dq-mediated activation of inhibitory NTS neurons affected inhibitory synaptic signaling to DMV motor
neurons. Application of CNO resulted in a significant increase in the frequency of inhibitory postsynaptic currents (IPSCs) in DMV motor neurons (9.3 ± 2.5 Hz in nACSF versus 12.2 ± 2.4 Hz in CNO; p = 0.04;
n = 8; Fig. 2c). The mean IPSC amplitude was not reliably changed by CNO (p = 0.2). These data indicate that
hM3Dq-mediated activation of GABAergic NTS neurons increases functional synaptic inhibition of the DMV.
Although pharmacological approaches have shown that GABAergic neurotransmission robustly modulates
DMV motor neuron activity43,44, we further investigated if the hM3Dq-induced increase in inhibitory neurotransmission to the DMV could alter motor neuron activity. Consistent with the increase in IPSC frequency,
the majority of DMV neurons exhibited a decrease in action potential firing after CNO application (≥15%
change: 6 decreased; 3 no change; 2 increased; n = 11; Fig. 2d). The decrease in action firing was accompanied
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Figure 2. Activation of GABAergic neurons in the DVC inhibits activity of neurons in the dorsal motor
nucleus of the vagus (DMV). (a) Top: Illustration of the synaptic pathway tested. A GABA neuron in the NTS
with a synaptic connection to a motor neuron in the DMV (X) is illustrated. Bottom: Illustration indicating
the location of recordings in the DMV. (b) Post hoc confirmation of the location of a recorded and biocytinfilled DMV neuron. No co-localization with mCherry was observed in DMV neurons. (c) Top: Spontaneous
inhibitory postsynaptic currents (sIPSCs) in a DMV neuron before and after CNO application. Bottom: Mean
sIPSC frequency and amplitude (n = 6). CNO significantly increased sIPSC frequency (p < 0.05), but not
amplitude. (d) Top: Action potential firing in a DMV neuron before and after CNO application. Bottom: Pie
graph illustrating the proportion of AP firing responses in DMV neurons to bath application of CNO (left)
and mean action potential (AP) frequency in the neurons in which a decrease in AP frequency was induced
by CNO (n = 5; p < 0.05; right). (e) Mean blood glucose concentration after in vivo systemic administration of
CNO (1 mg/kg) or vehicle (0.9% saline + 0.5% DMSO) in mice pre-treated with muscarinic receptor antagonist,
methylscopolamine (1 mg/kg; i.p.). There was no effect of CNO administration in the presence of MSA.
Asterisks indicate significant differences from time 0, but no differences between treatment groups.

by a hyperpolarization of the resting membrane potential of 3.4 ± 0.9 mV. This experiment was repeated in the
presence of the type A GABA receptor (GABAA) blocker, bicuculline methiodide (BIC; 30 µM; n = 4). In the
presence of bicuculline, CNO failed to decrease action potential firing in any neuron recorded, confirming that
GABAergic neurotransmission mediated the decrease in DMV neuron activity after CNO administration. These
results indicated that activation of GABAergic neurons in the DVC inhibits activity of vagal motor neurons and
that the hM3Dq DREADDs approach used here produced the anticipated cellular effects on the DVC.
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Figure 3. Peripheral pathway mediating CNO-induced hyperglycemia. (a) Illustration of hypothesized
pathway involved in the elevation of blood glucose after remote activation of GABAergic hindbrain neurons.
The inhibitory synaptic connection from NTS neurons to the DMV is shown, as is the increase in glucagon
release from the pancreas. Increased hepatic gluconeogenesis could result from decreased vagal input (shown)
and/or glucagon actions in the liver. (b) Change in blood glucose after 90 mins of vehicle, CNO (1 mg/kg), or
glucose (0.26 mg/kg) injection (i.p.). (c) Mean serum glucagon (left) and insulin (right) concentration 90 min
post-treatment. (d) Mean expression (fold change) of hepatic PEPCK1 mRNA expression (normalized to
β-actin expression). (e) Western blots indicated that pAKT/AKT and pLDHA/LDHA protein expression in
gastrocnemius muscle were unaltered at the same time point. For each protein, example blots were cropped
from the same gel, with boxes and lines added for clarity; exposures are unaltered. The full-length blots are
shown in Supplemental Fig. S4.

Modulation of Blood Glucose Concentration is Vagally-Mediated. Acetylcholine (ACh) released
from postganglionic parasympathetic neurons binds muscarinic receptors (mAChRs) in peripheral target cells,
and mAChR antagonists selectively block parasympathetic nervous system functions63. If activation of GABAergic
neurons in the DVC works through vagal parasympathetic pathways, we reasoned that blocking mAChRs peripherally would mitigate the effect of systemic CNO administration on blood glucose concentration. To test this
hypothesis, mice were systemically pre-treated with a mAChR antagonist that does not cross the blood-brain barrier, (−)-scopolamine methyl bromide (i.e., methylscopolomine; MSA; 1 mg/kg). Administration of MSA alone
significantly increased blood glucose concentration (Supplemental Fig. S2). Using a counter-balanced experimental design, the effect of CNO on blood glucose concentration was abolished when mAChRs were blocked by MSA
pre-administration (Repeated Measure ANOVA; p = 0.2; Fig. 2e). Taken together, these results demonstrate that
activation of hindbrain inhibitory circuits increases blood glucose via a GABAA- and mACh receptor-dependent,
vagally-mediated signaling pathway.
Peripheral Pathways Mediating CNO-Induced Hyperglycemia. To examine the potential peripheral
targets mediating DREADD-induced elevation in blood glucose concentration, vGAT-Cre mice injected with
the hM3Dq construct in the dorsal hindbrain mice were injected (i.p.) with either CNO, saline vehicle, or a bolus
of glucose (0.26 mg/kg) to mimic the elevation in the blood glucose concentration that was observed after CNO
injection. Mice were sacrificed after 90 mins and various tissues were assessed for their potential role in mediating the elevation in blood glucose concentration. Previous reports using optogenetic activation of hindbrain
glucose transporter 2 (Glut2)-expressing neurons suggested that vagal circuits can modulate pancreatic secretions36. Therefore, we tested plasma samples for markers of pancreatic hormone release. Consistent with that previous report, CNO-mediated activation of hindbrain GABAergic neurons elevated serum glucagon levels in vivo
(p = 0.01; n = 6; Fig. 3c). Of particular note, serum insulin concentration did not change (p = 0.66; n = 6; Fig. 3c).
Importantly, no differences existed between the vehicle-injected animals and those receiving a bolus of glucose
91.87 ± 12.9 versus 94.99 ± 13.11 IU/mL (Fig. 3c), indicating that the effect of CNO on glucagon concentration
Scientific Reports |
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Figure 4. Activation of the inhibitory hM4Di DREADD in GABAergic hindbrain neurons does not alter
blood glucose concentration or DMV neuron activity. (a) Diagram showing recording location in the NTS and
representative traces showing action potentials in an mCherry expressing NTS neuron before (left) and after
CNO (right; 10 μM) application in a mouse that received the hM4Di viral construct. (b) Mean AP firing and
membrane potential before and after CNO application (n = 8). *Significant difference from nACSF (paired
t-test; p < 0.05). (c) Diagram showing recording location in the DMV (left). Pie graph (right) illustrating
AP firing responses in NTS and DMV neurons. AP firing was decreased by CNO in NTS neurons but was
unchanged in most DMV neurons (n = 5). (d) Blood glucose concentration after in vivo administration of CNO
(1 mg/kg) or vehicle (0.9% saline + 0.5% DMSO). Asterisks indicate significant change from time 0, but no
differences between treatment groups.

was not simply in response to elevated glucose levels. These data demonstrate that activation of inhibitory signaling in the dorsal hindbrain increases glucagon release, and extend previous reports by demonstrating that this is
specific to glucagon release, since insulin concentration was not changed.
Since changes in insulin sensitivity can profoundly affect blood glucose concentration independently of
changes in total serum insulin levels, we tested whether peripheral insulin sensitivity was altered in skeletal muscle after GABAergic dorsal hindbrain activity. To accomplish this, we assessed AKT activation in gastrocnemius
muscle after DREADDs-mediated activation of GABA neurons in the DVC. Consistent with the lack of change
in serum insulin levels, there was no detectable change in the basal levels of Akt (ANOVA; p = 0.62), the phosphorylated state of Akt (pAKT; ANOVA; p = 0.31) or the ratio of pAKT/AKT (ANOVA, p = 0.07; Fig. 3e) 90 min
after CNO injection. A previous report demonstrated that brain-mediated remission of hyperglycemia involves
changes in lactate and pyruvate production in muscle tissue7. Therefore, we also examined lactate dehydrogenase
A activity (LDHA). There was a significantly lower level of LDHA in CNO-treated animals compared to both
vehicle- (ANOVA; p = 0.0004) and glucose-injected mice (p = 0.002) (Supplemental Fig. S3), consistent with
decreased lactate production in the muscle tissue. There was also a significantly lower level of activated/phosphorylated state LDHA (pLDHA) in the CNO-treated group versus glucose injected mice (ANOVA; p = 0.0073),
but neither of these groups were different from vehicle injected mice. Despite these difference in absolute LDHA
content, there was no significant difference in the ratio of pLDHA/LDHA across any of the groups (ANOVA,
p = 0.15) suggesting no consistent treatment related change occurred.
Previous reports suggested that hindbrain circuitry modulates blood glucose concentration through changes
in hepatic gluconeogenesis5,9. Similarly, we found a significant upregulation of hepatic phosphoenolpyruvate
caroboxykinase 1 (PEPCK1) expression in animals administered CNO (2−ddCt: 4.1 ± 1.3 fold; n = 10; p = 0.02;
Fig. 3d) compared to vehicle (n = 10). In mice receiving a single bolus of glucose, PEPCK1 expression (2−ddCt:
−0.7 ± 0.6; n = 7) was slightly lower than in vehicle-injected mice (≤20%) 90 min post-injection, but this was not
statistically significant (Fig. 3d; p = 0.6).

Decreasing Activity of GABAergic Hindbrain Neurons Using hM4Di-mCherry. Using the
same stereotaxic approach as previously described for hM3Dq, we virally transduced a separate cohort of
vGAT-Cre mice with AAV8-DIO-hM4Di-mCherry, the inhibitory form of the DREADDs. Recordings
from mCherry-labeled NTS neurons indicated a significant hyperpolarization after exposure to CNO
(ΔmV = −4.6 ± 1.2 mV; n = 5; 10 µM CNO; p = 0.008 paired t-test; Fig. 4a,b). This hyperpolarization was
accompanied by a significant decrease in action potential firing (2.0 ± 0.6 Hz, nACSF versus 1.2 ± 0.6 Hz, CNO;
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p = 0.002; n = 8). Action potential firing returned to baseline after a 15 minute washout to nACSF (p = 0.3).
Application of CNO reduced activity of mCherry-expressing NTS neurons, consistent with the expression of the
inhibitory DREADD construct in these neurons.

Inhibiting GABAergic Hindbrain Neurons does not Modulate Blood Glucose Concentration or
Vagal Motor Neuron Activity. The same counterbalanced experimental design as used for hM3Dq was

employed to test the effect of activating hM4Di in GABAergic hindbrain neurons. In this case, no change in blood
glucose concentration was detected after CNO injection in vGAT-Cre mice despite hM4Di’s significant dampening of activity of NTS circuitry in vitro (Fig. 4d). Therefore, despite robust glucose changes after GABAergic NTS
neuron activation using hM3Dq, dampening of activity in these same neurons with hM4Di did not evoke changes
in blood glucose concentration.
Based on the lack of effect on whole animal blood glucose concentration, we then tested whether
DREADDs-induced suppression of GABAergic hindbrain neuron activity affected GABAergic signaling to downstream DMV motor neurons. Application of CNO significantly decreased the frequency of IPSCs in recorded
DMV motor neurons (7.5 ± 2.2 Hz in nACSF versus 5.1 ± 1.6 Hz in CNO; p = 0.05; n = 7). Unlike the hM3Dq,
however, the amplitude of inhibitory events was also altered after hM4Di-dependent inhibition of GABAergic
hindbrain neurons, being reduced by ~10% (30.0 ± 2.3 pA in nACSF versus 26.9 ± 2.7 pA in CNO; p = 0.04;
n = 7). The effect of hM4Di activation on IPSC amplitude may be due to a reduction of synchronous release from
pre-synaptic terminals. Therefore, we concluded that hM4Di-expressing inhibitory NTS neurons indeed project
to the DMV and reducing their activity with CNO resulted in decreased GABA release in the DMV.
We then tested whether this dampened neurotransmission translated into disinhibition and increased action
potential firing of DMV motor neurons. Unlike CNO-mediated activation of GABAergic circuits, inhibition of
hM4Di-expressing GABA neurons with CNO did not produce consistent changes in DMV action potential firing (≥15% change: 1 decrease; 1 increase; 3 no change; n = 5; Fig. 4c). Although inhibitory synaptic input to the
DMV was decreased by activation of hM4Di in GABAergic neurons, DMV motor neuron activity was unaltered overall. This lack of effect on action potential firing in DMV motor neurons is consistent with the lack of
CNO-evoked changes in systemic blood glucose concentration.

Discussion

Despite our appreciation of fundamental autonomic pathways and principles, the role of parasympathetic output
in metabolic regulation, including maintenance of blood glucose concentration, is not well understood. Given
the importance of GABAergic inhibition in the modulation of parasympathetic drive to the subdiaphragmatic
viscera28,43,44,64,65, we investigated how dorsal hindbrain inhibitory neurons contribute to systemic blood glucose
regulation, using a chemogenetic approach to remotely activate/deactivate GABAergic inhibition within the dorsal hindbrain. Effects of DREADDs activation were investigated at the cellular level using patch-clamp recordings
in the NTS and DMV and cellular activity was subsequently linked to whole animal glucose metabolism. Results
here demonstrate that remote chemogenetic activation of GABAergic NTS neurons is sufficient to elevate blood
glucose concentration. Blocking mAChRs with MSA increased blood glucose concentration and prevented the
CNO-induced increase in glucose concentration, consistent with a vagally-mediated change in peripheral glucose
metabolism. The effect on blood glucose was paralleled by increased glucagon release in the absence of a change in
serum insulin concentration or insulin sensitivity; hepatic PEPCK1 expression was also increased, suggesting that
CNO also increased gluconeogenesis in the liver. The effects of CNO-dependent activation of hM3Dq-expressing
GABAergic NTS neurons on glucagon secretion and hepatic gluconeogenesis are consistent with a reduction in
vagally-mediated parasympathetic output to the pancreas and liver; the effect on hepatic PEPCK1 expression
could also be secondary to hormonal effects of elevated glucagon. Taken together, these results provide evidence
of a dorsal hindbrain mechanism for rapidly induced hyperglycemia, independent of insulin.
Recent studies have suggested that CNO-activated DREADD systems may not have the specificity initially
assumed due to possible effects of CNO metabolites, including clozapine58, but results here are consistent with
DREADDs-specific responses. Importantly, all of the effects we observed were restricted to animals that expressed
DREADDs within the DVC; animals that lacked hM3Dq DREADDs expression in GABAergic hindbrain neurons failed to exhibit any systemic or cellular effects of CNO. There were also divergent effects of the Gq and Gi
forms of DREADDs, which would be unexpected if CNO or its byproducts were binding endogenously expressed
receptors. Such off-target pharmacological effects would be expected to be identical, independent of the type of
DREADDs expressed, and should also have occurred when no DREADDs were expressed, neither of which was
the case. The in vitro patch-clamp studies demonstrated that DREADDs-mediated changes in either action potential firing or GABAergic neurotransmission were rapid (occurring in less than 5 mins), were consistent with the
expected excitatory or inhibitory actions of DREADDs activity, and failed to detect any complex or multimodal
effects of CNO that might indicate off-target effects of clozapine. The metabolic byproducts of CNO preferentially
affect DREADDs, with no off-target effects reported at doses similar to those used here, and were only apparent
after long exposure periods, during which accumulation of clozapine would be expected to increase its concentration58,66. Changes in blood glucose concentration began to occur by 15 min after a single CNO injection here,
which is not consistent with the >60 min required to detect initial effects attributable to clozapine. Thus, selectively increasing activity of GABAergic neurons in the dorsal hindbrain regulates whole animal blood glucose.
Much of the work suggesting that activation of vagal drive releases glucagon relies on indirect measures of
parasympathetic activity, specifically the release of pancreatic polypeptides50, although optogenetic activation of
a subset of inhibitory, Glut2-expressing NTS neurons paradoxically increased vagus nerve activity and glucagon
release in one study36, where the authors attributed the increase in vagal activity to the existence of a disinhibitory
circuit56 in the DMV. On the other hand, electrical stimulation of the DMV failed to alter blood glucose levels
in rats19. Direct measures of vagus nerve output can be contaminated by afferent activity, since the vagus nerve
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includes bidirectional vagal information that is dominated by afferent signaling. In one study, vagal afferent stimulation, which would be expected to activate most GABA neurons in the NTS, tended to increase blood glucose
concentration, while vagal efferent stimulation decreased blood glucose concentration67. DMV neurons can be
activated by antagonizing GABAA receptors44, and separate populations of pancreas-projecting DMV neurons
independently control endocrine versus exocrine secretions68. Here, hM3Dq-dependent activation of GABAergic
hindbrain neurons caused an increase in GABA release in the DMV, leading to a decrease in the activity of
most DMV motor neurons in vitro. The activation of hindbrain GABA neurons in vivo results in an elevation in
blood glucose concentration. Therefore, we suggest that inhibition, but not excitation, of vagal motor neurons
promotes the release of glucagon in the absence of a counter-regulatory release of insulin, at least at a time point
corresponding to peak glucose elevation. Notably, activity changes in other cell types (e.g., glutamatergic NTS
neurons42) could preferentially increase excitability of DMV motorneurons that regulate other metabolic regulatory systems, and such circuit-specific effects could account for the lack of significant effect on blood insulin
concentration following the CNO-induced increase in GABA neuron activity. In this scenario, a glutamate-driven
increase in DMV neuron activity might result in increased insulin release, which would be consistent with the
hypoglycemia reported after vagal efferent stimulation67. Further dissection of cell- and circuit-specific activity in
the dorsal vagal complex should reveal additional insight into hindbrain mechanisms that regulate metabolism.
The release of glucagon works to increase blood glucose concentration and drive hepatic production of
PEPCK1, and decreased vagal drive to the liver could also contribute to increased hepatic gluconeogenesis.
In the context of disease, chronic hyperglycemia elevates inhibitory, GABAA receptor-mediated signaling in
vagal motor neurons48,49, and this chronically elevated GABAergic inhibition of parasympathetic output may
play a role in reinforcing the hyperglycemia and hyperglucagonemia evident in diabetes69–71 and/or the loss of
counter-regulatory responses to hypoglycemia72,73. Although much work must be done to fully appreciate the
hindbrain’s role in metabolic disorders like diabetes, increased GABAergic signaling within the DVC, if sustained,
would thus be expected to contribute to maintaining diabetic hyperglycemia and inhibiting counter-regulatory
responses to glucose changes; it could also contribute to reinstatement of hyperglycemia during brief periods
of restored glycemic control. Elevated activity of brainstem inhibitory circuits therefore promotes hyperglycemia. The diabetes-related upregulation of central vagal GABA signaling reported previously45,48,49 may reinforce
hyperglycemia.
Blood glucose concentration can be bidirectionally modulated by manipulation of central hypothalamic components of the glucose regulatory system6. However, we detected no change in overall blood glucose concentration after DREADDs-induced inhibition of hindbrain GABAergic neurons. Using electrophysiological recordings
in vitro, we confirmed that hM4Di-expressing neurons were significantly hyperpolarized after CNO application
and that inhibitory neurotransmission to DMV neurons was significantly reduced. These changes in neurotransmission, however, were not enough to significantly increase DMV activity in vitro suggesting that, at least in
naïve mice, dampening of ongoing GABAergic signaling does little to alter overall DMV activity and subsequent
parasympathetic regulation of glucose metabolism. Under normal conditions in the slice preparation, GABA
release is relatively low, and slowing action potentials in hindbrain GABA neurons via hM4Di activity may only
modestly affect DMV neuron activity, if at all, especially since DMV motor neurons have intrinsic currents that
allow them to fire regularly in the absence of any neurotransmitter influence74. Conversely, a significant proportion of GABAA receptors are normally unoccupied in DMV neurons43,45,75, so increasing GABA release via
hM3Dq activation seems more likely to inhibit action potential firing in DMV neurons due to increased GABAA
receptor occupancy. Therefore, unlike hypothalamic circuitry, the activity of GABAergic neurons in the DVC
regulates blood glucose concentration in a mainly unidirectional fashion: They are directly implicated in elevating
blood glucose levels, but likely serve a more nuanced role (if any) in mediating decreases in blood glucose concentration. Consequently, activity in these neurons may serve as an evolutionary failsafe against hypoglycemia.
Paradoxically, it could also contribute to sustained hyperglycemia in diabetes, where results from mouse models
indicate that GABA sensitivity in DMV neurons is chronically increased45,48,49.
The DVC is a key autonomic regulatory region, receiving both peripheral afferent and descending hypothalamic and other central neural input. We and others have found that GABAergic neurons in this region are intrinsically sensitive to glucose in a glucokinase-dependent fashion35,36 and send significant, convergent projections to
DMV motor neurons42,44. As the final, central nexus for parasympathetic output, DMV neurons help orchestrate
signaling in peripheral organs in order to generate complex visceral responses, including those necessary to control energy homeostasis. Findings here directly link the activity of GABAergic neurons in the dorsal hindbrain to
systemic glucose metabolism. These results further our understanding of how parasympathetic output influences
energy homeostasis and support continued investigation of the role played by GABAergic hindbrain neurons in
the parasympathetic regulation of glucose metabolism in normal and diabetic states.

Materials And Methods
Animals.

All experiments were performed on Vgat-ires-Cre knock-in mice (i.e., vGAT-Cre mice;
Slc32a1tm2(cre)lowl/J; 016962; The Jackson Laboratory, Bar Harbor, ME). Mice were housed and cared for in the
University of Kentucky Division of Laboratory Animal Resources facilities according to protocols approved by the
University of Kentucky Animal Care and Use Committee.

Stereotaxic Viral Injections. At five weeks of age, mice were injected with floxed viral constructs (4 × 1012–

2.5 × 1013 virus molecules/mL; 250–500 nL) into the DVC under stereotaxic control (coordinates from bregma:
AP = 7.0 mm, ML = 1.0 mm, DV = 3.7 mm). Constructs, pAAV8-hSyn-DIO-hM3D(Gq)-mCherry (Addgene
plasmid # 44631) or pAAV8-hSyn-DIO-hM4D(Gi)-mCherry (Addgene plasmid # 44632), were a gift from Dr.
Bryan Roth and received from Addgene (Cambridge, MA). Mice were allowed to recover for one week following
surgery and then acclimated to handling for 3 weeks before the start of in vivo studies.
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Electrophysiology. At least four weeks after viral injections, slices were prepared as previously reported
using coronal brainstem slices in aCSF of a composition matching previous reports35,48. Coronal slices (300 µm)
containing the DVC were prepared and transferred to a holding chamber oxygenated (95%O 2/5%CO2) at
32–34 °C. On cell or whole-cell patch-clamp recordings were performed using glass pipettes (2–5 MΩ). Internal
recording solution composition matched previous reports35,48. Action potentials were recorded at resting membrane potential in current-clamp mode. DMV cells were voltage-clamped at a holding potential of 0 mV to record
IPSCs. Kynurenic acid (KYN; 1 mM) was added to perfusate for recordings in the DMV to block synaptic currents mediated by ionotropic glutamate receptors and isolate GABAergic currents; bicuculline methiodide (BIC;
30 µM) was used to block GABAA receptor-mediated currents.
All recordings were low-pass filtered at 3 kHz and acquired digitally at 20 kHz using pClamp acquisition software (Axon Clampfit; Molecular Devices, San Jose, CA). Mini-analysis (Synaptosoft, Decatur, GA) was used to
measure action potential firing and IPSC frequency and amplitude.
Single-cell RT-PCR.

Single-cell RT-PCR was performed as previously reported35. The oligonucleotides used
for PCR targeted β-actin (verifying the presence of constituent mRNA) and GAD67 (identifying GABAergic
cells). Cells were required to be positive for β-actin expression in order to be considered for analysis. Two control
samples were run: One contained reagents only (NTC); for the other, a pipette was filled with internal solution,
placed on the surface of the slice for five minutes and then the solution was expelled into an RNase-free PCR tube
exactly as when cell contents are collected.

In vivo Glucose Assessments.

Four weeks after viral delivery, mice were randomly selected to receive
either vehicle (0.9% saline + 0.5% DMSO) or CNO (1 mg/kg). Mice were fasted for two hours before getting an
i.p. injection of either vehicle, CNO, or glucose (0.26 g/kg; to match the rise after CNO administration). Animals
remained fasted and blood glucose was measured (tail vein lance; OneTouch Ultra) for 5 hrs. One cohort was
pre-treated with MSA (1 mg/kg; i.p.) 15 min prior to CNO or vehicle injection. Each animal received the opposite
treatment 3–4 days later to provide a counter-balanced design. Data are expressed as the change in blood glucose
measured immediately prior to injection.

Immunohistochemistry and Imaging. All injection sites were confirmed after experiment termination
using endogenous mCherry expression. To confirm electrophysiological recording locations, slices were fixed and
biocytin (0.1%) filled neurons were stained for avidin-AMCA (1:400; Vector Laboratories, Burlingame, CA) after
recording as previously described35,76,77. Imaging was done with an Olympus BX40 microscope, and images were
captured with a Spot RT camera (Diagnostic Instruments, Burroughs, MI) using filters for the two fluorescent
dyes (Fig. 1).
Western Blots.

Frozen tissues were homogenized in RIPA buffer with Halt Protease Inhibitor Cocktail
(Thermo Fisher 78430) and Halt Phosphatase Inhibitor (Thermo Fisher 78420). Concentration was measured
using DC Protein Assay (Biorad 5000116). Samples were boiled with SDS sample buffer for loading. Protein
homogenate (30 µg) in SDS sample buffer was subjected to SDS-PAGE and transferred onto PVDF membranes.
Membranes were blocked with 5% milk in TBS-T (TBS, 0.1% TWEEN 20). Membranes were incubated overnight
at 4 °C with primary antibodies (1:1,000) from Cell Signaling phospho-LDHA (#8176), LDHA (#2012), AKT
(#9272), phospho-AKT S473 (#4058). Membranes were washed in TBS-T and incubated for 1 h at room temperature with the secondary antibody (Invitrogen A21109). Fluorescent secondary antibody was detected on Licor
Odyssey and analysis of band intensity was performed in ImageJ.

Data Analysis.

Recordings were analyzed using Clampfit 10.2 (Molecular Devices) and MiniAnalysis 6.0.7
software (Synaptosoft). For analysis of postsynaptic currents and action potential firing, two minutes of continuous recording under each condition was used. Changes in action potential firing in DMV neurons from
baseline of ≥15% were considered significant. Group mean ± standard error of the mean (SEM) is reported. A
repeated-measures ANOVA with Tukey’s post hoc was used to determine if CNO injection significantly changed
blood glucose. For all other data, a paired or unpaired, two-tailed Student’s t-test was used to determine statistical
significance (Graphpad Prism; La Jolla, CA). Unless otherwise stated, statistical significance for all measures was
set at p ≤ 0.05.

Data Availability

The authors will make materials, data and associated protocols promptly available to readers without undue qualifications in material transfer agreements.
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